Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Featured Stories


Doubts Raised Over Regeneron’s Anti-IL 33 REGN3500 At Phase II In Asthma

Topline data from a Phase II proof-of-concept study evaluating anti-IL-33 monotherapy REGN3500 (SAR440340) in asthma suggest it is not as effective as Dupixent and that there is no incremental benefit from adding it to Dupixent.

Clinical Trials Companies Respiratory

Sanofi Plans More Job Cuts, This Time In R&D

The French pharma giant will cut 466 posts in France and Germany. Cardiovascular and diabetes research will be scaled back.

Research and Development Strategies France Germany

Finance Watch: Investors Bet On Hope As Four Early-Stage Companies Launch US IPOs

Public Company Edition: Of five drug developers expected to go public, four have preclinical or early clinical candidates, while the one that could not find a market for its IPO is in Phase III. Also, Biohaven, Zymeworks and Kura raise $100m or more in follow-on offerings.

Financing Business Strategies Innovation
Advertisement


 Recent Tweets from Scrip


PRECISION MEDICINE RESEARCH: How Advanced Data Analytics Support The Journey From Clinic to Bedside

Precision medicine offers huge promise to patients and health systems. It can also substantially increase the efficiency of drug development by enabling more focused, data-rich clinical trials.

Read more

Embedding Time-Critical Scheduling in Drug Production

Manufacturing is the engine room of the pharmaceutical industry. Ultimately, a medicine has little value if it does not reach patients on schedule, in the required quantity and quality. Download this whitepaper which discusses time-critical scheduling in drug production.

Download Whitepaper
Advertisement

 

Commercial Explore this Topic

Set Alert for Commercial

Novumcella Building Exosome Expertise In Inflammatory Disorders

Tokyo-based Novumcella Inc. is progressing several still preclinical stage assets derived from academic research, with a focus on the intractable inflammatory disease area, and is looking to secure new financing and partners as it considers an IPO down the road.

Japan Regenerative Medicine Inflammation

Keytruda Rules The Roost, But Merck & Co. Highlights Progress In Other Areas

Merck & Co. outlined its near-term growth drivers during an investor day, including Keytruda in breast and prostate cancer, as well as vaccines for RSV and CMV, a drug for chronic cough and a long-acting HIV medicine.

Business Strategies Clinical Trials ImmunoOncology

Chugai Expects Limited Impact From First Biosimilar To Top Seller

First biosimilar version of Avastin approved in Japan, posing the first direct threat to Chugai's top product. But indications and timings mean the company expects limited impact this year.

Japan Biosimilars

Product Licensing Deals In India Paying Off?

India has seen an uptick in in-licensing deals, with robust growth in the number of novel drugs in such arrangements delivering gains for both the domestic partner and innovator company.

India Commercial

Lupin Boss On Getting Biosimilar Manufacturing Right, Albuterol Outlook

Lupin managing director tells Scrip that manufacturing competence will be a “big advantage” in the biosimilars space, and also believes that the US albuterol market remains “very lucrative” despite the entry of authorized generics.

Commercial Strategy

Genexine Hopes To Become 'Asia’s Amgen' After ToolGen Merger

With an ambition to become an Amgen-like global biopharma, South Korea's Genexine decides to merge with local genome editing firm ToolGen to progress potential global blockbusters such as universal CAR-T therapies.

South Korea M & A

Ready To Ride Next Growth Wave In China? Remember Five Keys

As China enters a new growth spur for the health sector, underscored by faster product approvals, annual reimbursement coverage and strong demand for high-quality treatments, strategic planning and meticulous execution are more important than ever if companies want to win in the world's second-largest pharma market, says a new report.

China Market Access

Deal Watch: Sanofi Further Opts Out Of CNS Tie-Up With Voyager

Sanofi returns two partnered assets to Voyager, further unraveling 2015 deal. Celgene drops Mereo cancer candidate ahead of merger with Bristol, while Ultragenyx and Arcturus expand their joint rare disease efforts.

Business Strategies Commercial

Policy & Regulation Explore this Topic

Set Alert for Policy & Regulation

Vaccines Face Biggest Safety & Efficacy Resistance From Eastern Europe

Wellcome Trust survey notes that while 79% of people agree vaccines are safe and 84% say they are effective, Eastern Europe and France are among the most skeptical about them.

Vaccines Infectious Diseases Safety

No-Deal Brexit 'Very Bad' For Business And Patients

Peter Martin, COO of Norgine, is concerned about the ‘mood music’ in the political environment in the UK, and warns about the risks of the UK leaving the EU without a deal in place.

Brexit Trade

Japanese OK In COPD Gives AstraZeneca’s Breztri Aerosphere First Regulatory Approval

AstraZeneca’s respiratory chief tells Scrip Japan’s approval of the triple-combination inhaled therapy is both a milestone for treating COPD and for the UK pharma’s strategy.

Policy Approvals

US FDA Approval Of Novo Nordisk's Victoza For Young T2D Patients A Treatment Milestone

The new indication means Victoza is the first non-insulin drug approved to treat type 2 diabetes in young patients since metformin was approved for pediatric use in 2000. Victoza has been approved to treat adult patients with type 2 diabetes since 2010.

Approvals Companies

Research & Development Explore this Topic

Set Alert for Research & Development

Bayer’s Stivarga First Drug To Enter Brain Cancer Platform Trial

GBM AGILE is the first global adaptive clinical trial platform for glioblastoma and the German group's liver and colorectal cancer drug will be the first of several therapies to be studied.

Cancer Clinical Trials Companies

UCB Buoyed By More Positive Bimekizumab Data

The Belgian group has a lot of catching up to do with Cosentyx and Taltz already well established but is confident bimekizumab’s mechanism of action, which neutralizes both IL-17A and IL-17F cytokines, offers an advantage over those two blockbusters.

Immune Disorders Clinical Trials

Sanofi’s Ameet Nathwani Brings Life Sciences R&D Expertise To The Digital Space

Nathwani talks to Scrip about his unique dual role as chief medical officer and chief digital officer, Sanofi’s approach to digital therapeutics, and major hurdles to turning the promise of such technologies into a reality for patients.

Digital Health Exec Chat

Dosing Woes For VBI Vaccines As Share Price Plummets On Hep B Study Results

Despite positive results in the latest Phase III PROTECT study of its hepatitis B vaccine, VBI Vaccines failed to show non-inferiority at two doses, leaving it trailing behind competitor Dynavax and its established two-dose product.

Infectious Diseases Vaccines
UsernamePublicRestriction

Register

Advertisement